2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

  title={2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).},
  author={Giuseppe Mancia and Robert H. Fagard and Krzysztof Narkiewicz and Josep Red{\'o}n and Alberto Zanchetti and Michael B{\"o}hm and Thierry Christiaens and Renata C{\'i}fkov{\'a} and Guy G. De Backer and Anna F. Dominiczak and Maurizio Galderisi and Diederick E. Grobbee and Tiny Jaarsma and Paulus Kirchhof and Sverre E. Kjeldsen and St{\'e}phane Laurent and Athanasios J. Manolis and Peter M. Nilsson and Luis M. Ruilope and Roland E. Schmieder and Per Anton Sirnes and Peter Sleight and Margus Viigimaa and Bernard Waeber and Faiez Zannad and Michel Burnier and Ettore Ambrosioni and Mark J. Caufield and Antonio Coca and Michael Hecht Olsen and Costas P. Tsioufis and Philippe van de Borne and Jos{\'e} Luis Zamorano and Stephan Achenbach and Helmut Baumgartner and Jeroen J. Bax and H{\'e}ctor Bueno and Ver{\'o}nica Dean and Christi Deaton and Çetin Erol and Roberto Ferrari and David Hasdai and Arno W Hoes and Juhani Knuuti and Philippe H. Kolh and Patrizio Lancellotti and Ale{\vs} Linhart and Petros Nihoyannopoulos and Massimo Francesco Piepoli and Piotr Ponikowski and Juan Tamargo and Michal Tendera and Adam Torbicki and William Wijns and Stephan Windecker and Denis L. Clement and Thierry C. Gillebert and Enrico Agabiti Rosei and Stefan D. Anker and Johann Bauersachs and Jana Brguljan Hitij and Mark J. Caulfield and Marc L. De Buyzere and Sabina M De Geest and Genevi{\`e}ve Derumeaux and Serap Erdine and Csaba Farsang and Christian Funck-Brentano and Vjekoslav Gerc and Giuseppe German{\'o} and Stephan Gielen and Hermann Haller and Jens Jordan and Thomas Kahan and Michel Komajda and Dragan B. Lovic and Heiko Mahrholdt and Jan Ostergren and Gianfranco Parati and Joep Perk and Jorge Junqueira Pol{\'o}nia and Bogdan Alexandru Popescu and Željko Reiner and Lars Ryd{\'e}n and Yu.N. Sirenko and Alice V. Stanton and Harry A. J. Struijker‐Boudier and Charalambos Vlachopoulos and Massimo Volpe and David A. Wood},
  journal={European heart journal},
  volume={34 28},
ABCD : Appropriate Blood pressure Control in Diabetes ABI : ankle–brachial index ABPM : ambulatory blood pressure monitoring ACCESS : Acute Candesartan Cilexetil Therapy in Stroke Survival ACCOMPLISH : Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension ACCORD : Action to Control Cardiovascular Risk in Diabetes ACE : angiotensin-converting enzyme ACTIVE I : Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events… 

2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.

The If Inhibitor Ivabradine in Patients With Coronary Artery Disease and Left Ventricular Dysfunction is evaluated as well as patients with Diabetes mellitus for Optimal management of Multivessel disease.

2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA)

This paper focuses on the treatment of chronic kidney disease through the lens of endovascular aortic aneurysm repair, and the role of stent placement in this process.

Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension

This paper proposes that this core drug treatment strategy is also applicable for hypertensive patients with HFpEF with the addition of some modifications and indicates that novel agents such as sodium-glucose co-transporter-2 inhibitors, and finerenone represent promising therapies and results from ongoing RCTs are eagerly awaited.

Achieving blood pressure targets for prolonged cardiovascular health: a historical perspective

  • S. Chrysant
  • Medicine
    Expert review of cardiovascular therapy
  • 2017
The recent publication of the Systolic Blood Pressure Intervention Trial (SPRINT) has challenged guidelines by showing that aggressive SBP control to < 120 mmHg was associated with significant CV benefits.

Target Blood Pressure Level in the Management of Hypertension

Clinical trials showed that control of hypertension by life style modification and pharmacological interventions reduce the risk of complications like stroke, myocardial infarction and heart failure, and beta blocker has been advocated in case of compelling ground.

Average Clinician‐Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial

Average BPs <130/80 mm Hg were associated with worsened cardiovascular outcomes, and data suggest that intensive control of BP in patients with type 2 diabetes mellitus and ischemic heart disease should be evaluated in a prospective randomized trial.

Creatinine Rise During Blood Pressure Therapy and the Risk of Adverse Clinical Outcomes in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of the ACCORD-BP Randomized Controlled Trial

The data suggest that a >30% serum creatinine increase that coincides with lower blood pressure values should not directly lead to a reduction in antihypertensive medication in patients with type 2 diabetes mellitus.

The Impact of Different Antihypertensive Drugs on Cardiovascular Risk in Isolated Systolic Hypertension with Type 2 Diabetes Patients

ARB may alleviate the cardiovascular risks in ISH with T2DM patients, but ACEI, CCB, and TD did not.

Intensive Blood Pressure Lowering in Patients With and Patients Without Type 2 Diabetes: A Pooled Analysis From Two Randomized Trials

Intensive blood pressure lowering may have a similar favorable effect and appears to decrease cardiovascular events in both patients with and patients without T2DM.

Impact of age on clinical outcomes of antihypertensive therapy in patients with hypertension and coronary artery disease: A sub‐analysis of the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease

In the contemporary era of aggressive coronary revascularization, a lower SBP target may be appropriate even in elderly patients with hypertension and CAD, post hoc analysis from the HIJ‐CREATE trial suggests.



What Is the Optimal Blood Pressure in Patients After Acute Coronary Syndromes?: Relationship of Blood Pressure and Cardiovascular Events in the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction (PROVE IT-TIMI) 22 Trial

After acute coronary syndrome, a J- or U-shaped curve association existed between BP and the risk of future cardiovascular events, with lowest event rates in the BP range of approximately 130 to 140mm Hg systolic and 80 to 90 mm Hg diastolic and a relatively flat curve, which suggests that too low of a pressure may be dangerous.

Left Atrial Size and Risk of Major Cardiovascular Events During Antihypertensive Treatment: Losartan Intervention for Endpoint Reduction in Hypertension Trial

Left atrial diameter/height predicts risk of cardiovascular events independent of other clinical risk factors in hypertensive patients with left ventricular hypertrophy and may be useful in pretreatment clinical assessment of cardiovascular risk in these patients.

Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study

In high-risk patients, the benefits from SBP lowering below 130 mmHg are driven mostly by a reduction of stroke; myocardial infarction is unaffected and cardiovascular mortality is unchanged or increased.

Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.

Low-dose diuretic-based (chlorthalidone) treatment is effective in preventing major CVD events, cerebral and cardiac, in both non-insulin-treated diabetic and nondiabetic older patients with ISH, with few adverse effects.

Ambulatory blood pressure monitoring and development of cardiovascular events in high-risk patients included in the Spanish ABPM registry: the CARDIORISC Event study

Night-time ABPM performed during treatment adds prognostic significance on the development of cardiovascular events in high-risk hypertensive patients, and among different ABPM-derived values, night-time SBP is the most potent predictor of outcome.

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive and should be preferred for first-step antihypertensive therapy.